Affymax

About:

Affymax is a biopharmaceutical company.

Website: http://www.affymax.com

Top Investors: Bessemer Venture Partners, Apax Partners, JAFCO Asia, MPM Capital, ProQuest

Description:

Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's first product candidate, peginesatide (formerly known as Hematideâ„¢), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidney disease (CKD). A New Drug Application (NDA) for peginesatide for the treatment of anemia associated with CKD in adult patients on dialysis is currently being reviewed by the U.S. Food and Drug Administration (FDA).

Total Funding Amount:

$173M

Headquarters Location:

Cupertino, California, United States

Founded Date:

2001-01-01

Contact Email:

info(AT)affymax.com

Founders:

Prashant Tyagi

Number of Employees:

251-500

Last Funding Date:

2009-03-03

IPO Status:

Public

Industries:

© 2025 bioDAO.ai